Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
395 pending office actions • 190 clients • 326 examiners • 129 art units • 0 of 395 (0%) have an AI response strategy ready
This profile covers Biotechnology & Pharmaceuticals and shows 392 pending office actions. The record includes 12363 career applications, indicating a substantial prosecution portfolio with a large active workload.
The resolved allowance rate is 74.48%, and the average is 3.52 office actions per allowance. Resolved outcomes show that allowances occurred in a majority of matters, while the action average indicates that allowance commonly followed several examination events.
The scale of the pending docket makes prioritization and consistent response strategy important. Practitioners can use the allowance rate to frame expected outcome performance and the action average to anticipate the examination effort associated with moving matters toward allowance.
Based on the USPTO statutory response window for each pending office action. 116 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 116 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 4 (1%) |
| §101 + other | 47 (12%) |
| §103 only | 86 (22%) |
| §102 only | 11 (3%) |
| §112 only | 25 (6%) |
| Double-patenting only | 19 (5%) |
| Double-patenting + other | 53 (13%) |
| Multi-statute (no §101) | 144 (36%) |
| No statute on record | 6 (2%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GOLLAMUDI, NEERAJA | 4 | 72.6% | +40.0% |
| SMALE, AVERY E | 4 | 72.6% | +18.4% |
| HASAN, KHALEDA B | 4 | 59.3% | +49.0% |
| GODDARD, LAURA B | 3 | 50.8% | +13.6% |
| GONZALEZ, LEI NMN | 3 | 42.9% | +51.8% |
| NESTOR, DONNA MICHELLE | 3 | 56.6% | +44.2% |
| KALISZEWSKI, ALINA ROSE | 3 | 84.6% | +23.3% |
| OSENBAUGH-STEWART, ELIZA W | 3 | 73.0% | +16.8% |
| LADD, CAROLYN LOUISE | 3 | 58.6% | +47.1% |
| RYAN, DOUGLAS CHARLES | 3 | 38.2% | +48.4% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998012 | AN ATMOSPHERIC PRESSURE IONISATION SOURCE | KALISZEWSKI, ALINA ROSE | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18612960 | Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs | HUYNH, PHUONG N | 238d overdue |
| 18145772 | SARS-COV-2 SERUM ANTIBODY PROFILING | ZOU, NIANXIANG | 162d overdue |
| 17800958 | METHODS AND COMPOSITIONS FOR MODULATING ARGININE LEVELS IN IMMUNE CELLS | DHAR, MATASHA | 147d overdue |
| 17879923 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | JAVANMARD, SAHAR | 147d overdue |
| 17157043 | Dynamically Changing Promotions Displayed on a Mobile Device and Measuring The Benefit Thereof | OSMAN BILAL AHMED, AFAF | 147d overdue |
| 18085792 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | JAVANMARD, SAHAR | 142d overdue |
| 18042375 | NEBULIZER DEVICE OPTIMIZATION FOR IMPROVED AEROSOL PARAMETERS AND USES THEREOF | PINDERSKI, JACQUELINE M | 104d overdue |
| 17552935 | METHODS, MEDIUMS, AND SYSTEMS FOR BUILDING AND EXECUTING A CHROMATOGRAPHY WORKFLOW | GAVIN, KRISTIN ELIZABETH | 99d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18306041 | COMPRESSION DETECTION AND COMPENSATION FOR A BIOLOGICAL SENSOR SECURED TO A USER | GONZALEZ, LEI NMN | 58d overdue |
| 18042193 | A METHOD FOR THE ISOLATION OF DOUBLE-STRAND BREAKS | RYAN, DOUGLAS CHARLES | 3d overdue |
| 19284259 | SYSTEMS AND METHODS FOR DENTAL TREATMENT WITH EKF | GONZALEZ, LEI NMN | 14d |
| 18454323 | SYSTEM AND METHOD FOR ADJUSTING INSULIN DELIVERY TO ACCOUNT FOR INSULIN RESISTANCE | GONZALEZ, LEI NMN | 26d |
| 17749449 | METHODS, MEDIUMS, AND SYSTEMS FOR PROVIDING ASSISTED CALIBRATION FOR A MASS SPECTROMETRY APPARATUS | OSENBAUGH-STEWART, ELIZA W | 34d |
| 17639401 | METHODS OF TREATING EPILEPSY USING THE SAME | NESTOR, DONNA MICHELLE | 60d |
| 19569819 | TRISPECIFIC COMPOSITIONS COMPRISING IL-2, VEGF BINDING DOMAINS, AND PD-1 BINDING DOMAINS | GODDARD, LAURA B | — |
| 18980378 | VPS34 INHIBITORS AND METHODS OF USE THEREOF | NESTOR, DONNA MICHELLE | — |
| Art Unit | Apps |
|---|---|
| 3783 | 44 |
| 1618 | 12 |
| 2881 | 12 |
| 1636 | 10 |
| 1642 | 9 |
| 1635 | 9 |
| 1627 | 9 |
| 1625 | 8 |
| 1626 | 8 |
| 1623 | 8 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19569819 | TRISPECIFIC COMPOSITIONS COMPRISING IL-2, VEGF BINDING DOMAINS, AND PD-1 BINDING DOMAINS | Bright Peak Therapeutics AG | GODDARD, LAURA B | 1642 | §103§112DP | Non-Final OA | — | Pending | Mar 17, 2026 |
| 19548526 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | University of Basel | PERREIRA, MELISSA JEAN | 1618 | §102§103DP | Non-Final OA | — | Pending | Feb 24, 2026 |
| 19545401 | FORMULATIONS OF VIMSELTINIB | Deciphera Pharmaceuticals, LLC | PAK, JOHN D | 1699 | §103§112DP | Final Rejection | — | Pending | Feb 20, 2026 |
| 19544595 | FORMULATIONS OF VIMSELTINIB | Deciphera Pharmaceuticals, LLC | LEE, SIN J | 1613 | §102§103§112 | Final Rejection | — | Pending | Feb 19, 2026 |
| 19434846 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RADIATION INDUCED TOXICITY | Zydus Lifesciences Limited | OH, TAYLOR V | 1625 | §103 | Final Rejection | — | Pending | Dec 29, 2025 |
| 19433697 | METHODS OF TREATING AGE-RELATED MACULAR DEGENERATION | Character Biosciences, Inc. | HELLMAN, KRISTINA M | 1654 | §112 | Final Rejection | — | Pending | Dec 26, 2025 |
| 19432924 | AN IMPROVED PROCESS OF PURIFICATION OF PROTEIN | Kashiv Biosciences, LLC | REGLAS, GEORGIANA C | 1651 | §102 | Final Rejection | — | Pending | Dec 24, 2025 |
| 19432904 | AN IMPROVED PROCESS OF PURIFICATION OF PROTEIN | Kashiv Biosciences, LLC | MCDERMOTT, JEANNIE | 1776 | §103§112Other | Non-Final OA | — | Pending | Dec 24, 2025 |
| 19425391 | USE OF CYCLODEXTRINS AS A RADIOSTABILIZER | GE Healthcare Limited | MEJIAS, SAMANTHA LEE | 1618 | §103 | Non-Final OA | — | Pending | Dec 18, 2025 |
| 19397828 | TREATMENT OF DIABETIC RETINOPATHY USING ENDOTHELIN RECEPTOR ANTAGONISTS | Perfuse Therapeutics, Inc. | BASQUILL, SEAN M | 1614 | §103 | Final Rejection | — | Pending | Nov 21, 2025 |
| 19348728 | ORAL MUCOSAL FORMULATIONS OF ASPIRIN | Aspire Biopharma Holdings, Inc. | SONG, JIANFENG | 1613 | §103DP | Final Rejection | — | Pending | Oct 02, 2025 |
| 19344208 | CRYOGENIC COOLING SYSTEM WITH A RESONANT EXPANDER | R7 Instruments, Inc. | LARGI, MATTHEW THOMAS | 3746 | §102§112 | Final Rejection | — | Pending | Sep 29, 2025 |
| 19339016 | TIERED TESTING FOR HIGH RISK POPULATIONS | Harbinger Health, Inc. | SMITH, EMILIE ALINE | 1686 | §101§112DP | Non-Final OA | — | Pending | Sep 24, 2025 |
| 19338730 | TRANSDERMAL DEXMEDETOMIDINE FOR TREATING AGITATION | Teikoku Pharma Usa, Inc. | HAVLIN, ROBERT H | 1626 | §103DP | Final Rejection | — | Pending | Sep 24, 2025 |
| 19288411 | MULTI-TIERED TESTING FOR TRACKING DISEASE HETEROGENEITY | Flagship Pioneering Innovations Vi, LLC | SKIBINSKY, ANNA | 1635 | §101§103 | Non-Final OA | 50d overdue | Pending | Aug 01, 2025 |
| 19284259 | SYSTEMS AND METHODS FOR DENTAL TREATMENT WITH EKF | T33 Dental, Inc. | GONZALEZ, LEI NMN | 3783 | §103 | Final Rejection | 14d | Pending | Jul 29, 2025 |
| 19282184 | PROCESS OF PURIFICATION OF PROTEIN | Kashiv Biosciences, LLC | ROONEY, NORA MAUREEN | 1641 | §112DP | Non-Final OA | — | Pending | Jul 28, 2025 |
| 19244554 | METHODS TO MODIFY BEHAVIORS TO MITIGATE IMPACT OF PREDICTION INACCURACIES FOR LATER TIME WINDOWS IN AMD SYSTEMS | Insulet Corporation | GILLIGAN, CHRISTOPHER L | 3683 | §103 | Final Rejection | — | Pending | Jun 20, 2025 |
| 19220387 | SYSTEMS AND METHODS FOR DETERMINING ASSET IMPORTANCE IN SECURITY RISK MANAGEMENT | Bitsight Technologies, Inc. | MANIWANG, JOSEPH R | 2453 | DP | Non-Final OA | — | Pending | May 28, 2025 |
| 19211805 | ON-BODY INTERLOCK FOR DRUG DELIVERY DEVICE | Insulet Corporation | STIGELL, THEODORE J | 3783 | §103§112DP | Non-Final OA | — | Pending | May 19, 2025 |
| 19197571 | SYSTEMS AND METHODS FOR DATA STRUCTURE ANALYSIS | Gestalt Tech Corp. | SAMARA, HUSAM TURKI | 2161 | §103 | Final Rejection | 36d overdue | Pending | May 02, 2025 |
| 19196457 | IgE PROTEASES AND USES THEREOF | Seismic Therapeutic, Inc. | DESAI, ANAND U | 1655 | §102§103§112 | Non-Final OA | — | Pending | May 01, 2025 |
| 19187537 | ELECTROCHEMICAL ACTUATORS AND ACTUATOR ARRAYS | Insulet Corporation | LETTMAN, BRYAN MATTHEW | 3746 | §103 | Final Rejection | 43d | Pending | Apr 23, 2025 |
| 19180988 | EARLY MEAL DETECTION AND CALORIE INTAKE DETECTION | Insulet Corporation | DUNHAM, JASON B | 3686 | §101§103 | Non-Final OA | — | Pending | Apr 16, 2025 |
| 19172026 | IMAGE-BASED DETECTION OF OPHTHALMIC AND SYSTEMIC DISEASES | Antinous Technology Company Limited | WINDSOR, COURTNEY J | 2661 | §102§103Other | Non-Final OA | — | Pending | Apr 07, 2025 |
| 19171119 | SYSTEM TO CREATE CELLULAR LYSIS AND DELIVER FLUIDS INTRATUMORALLY | Syncromune, Inc. | SHOULDERS, ANNIE LEE | 3794 | §102§103 | Non-Final OA | — | Pending | Apr 04, 2025 |
| 19087070 | POLY-DONOR CD4+ T CELLS EXPRESSING IL-10 AND USES THEREOF | Tr1X, Inc. | NGUYEN, QUANG | 1631 | §103§112Other | Non-Final OA | — | Pending | Mar 21, 2025 |
| 19084902 | AUTOMATED PLATFORM FOR GENERATING INTERACTIVE VIDEOS | Jbf Interlude 2009 Ltd. | OCAK, ADIL | 2426 | §103 | Final Rejection | — | Pending | Mar 20, 2025 |
| 19079820 | IMAGE-GUIDED ROBOTIC SYSTEM WITH REMOTE GUIDANCE, IMAGE STEERING, MULTI-PLANE IMAGING, NEEDLE VISUALIZATION ENHANCEMENT, AND CONSTRAINED BACKDRIVING | Mendaera, Inc. | BRUTUS, JOEL F | 3797 | §103 | Final Rejection | 30d overdue | Pending | Mar 14, 2025 |
| 19073748 | SYSTEMS AND METHODS FOR CUSTOMIZING ONLINE GAMING | Magnetic Games AB | ADAMS, CARL | 2627 | §102§103 | Non-Final OA | — | Pending | Mar 07, 2025 |
| 19068816 | ION IDENTIFICATION USING ION MOBILITY SPECTROMETRY | Micromass UK Limited | LE, THANG XUAN | 2858 | §102Other | Non-Final OA | — | Pending | Mar 03, 2025 |
| 19047061 | METHODS AND SYSTEMS FOR ANALYZING IMAGES FOR PRECISION TISSUE MICROARRAY CONSTRUCTION | Noetik Inc. | CROCKETT, JOSHUA BRIGHAM | 2661 | §103§112 | Non-Final OA | — | Pending | Feb 06, 2025 |
| 19039593 | FABRICATION OF POLYCRYSTALLINE SILICON NITRIDE FIBERS | Bluehalo, LLC | DAIGLER, CHRISTOPHER PAUL | 1741 | §101§103 | Non-Final OA | — | Pending | Jan 28, 2025 |
| 19035537 | APPARATUS FOR GLYCEMIC CONTROL | Insulet Corporation | KOLOSOWSKI-GAGER, KATHERINE | 3687 | §101§103 | Final Rejection | 42d overdue | Pending | Jan 23, 2025 |
| 19022962 | METHOD AND SYSTEM FOR ASSET ROUTING | Lob.Com, Inc. | WALLACE, JOHN R | 2682 | §103Other | Non-Final OA | — | Pending | Jan 15, 2025 |
| 19022649 | METHOD FOR PREPARING METALLIC COBALT THIN FILM AND METHOD FOR PREPARING COBALT SILICIDE THIN FILM | BEIJING SUPERSTRING ACADEMY OF MEMORY TECHNOLOGY | TALBOT, BRIAN K | 1712 | §103§112 | Final Rejection | — | Pending | Jan 15, 2025 |
| 19013936 | SYSTEMS AND METHODS FOR UNDERGROUND STORAGE OF STORM AND OTHER WATER SOURCES | Underground Industries LLC | TOLEDO-DURAN, EDWIN J | 3678 | §102§103§112Other | Non-Final OA | — | Pending | Jan 08, 2025 |
| 19012213 | SYSTEM AND METHOD FOR TREATMENT OF MEDICAL CONDITIONS USING MULTIPLE BLOOD PRESSURE SENSORS | Aktiia SA | YOON, CHANEL J | 3791 | §101§103§112 | Non-Final OA | — | Pending | Jan 07, 2025 |
| 19004969 | LOGGING AND ANALYZING ROBOTIC PICKING DATA | Oxipital AI Inc. | NELESKI, ELIZABETH ROSE | 3658 | §103 | Final Rejection | 14d | Pending | Dec 30, 2024 |
| 18985953 | METHOD FOR MANUFACTURING A NEW PROSTHESIS | Ottobock SE & Co. Kgaa | ERDMAN, CHAD G | 2116 | §102§103§112 | Non-Final OA | — | Pending | Dec 18, 2024 |
| 18980378 | VPS34 INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC | NESTOR, DONNA MICHELLE | 1627 | §103§112 | Non-Final OA | — | Pending | Dec 13, 2024 |
| 18974588 | NINTEDANIB AND NINTEDANIB COMBINATION DRY POWDER COMPOSITIONS AND USES | Avalyn Pharma Inc. | ZHANG SPIERING, DONGXIU | 1616 | §103§112DP | Non-Final OA | — | Pending | Dec 09, 2024 |
| 18971800 | SOLID FORMS OF AN ULK INHIBITOR | Deciphera Pharmaceuticals, LLC | SEITZ, ANTHONY JOSEPH | 1629 | §103§112 | Non-Final OA | — | Pending | Dec 06, 2024 |
| 18870188 | SYSTEM AND METHODS FOR PREDICTING GLAUCOMA INCIDENCE AND PROGRESSION USING RETINAL PHOTOGRAPHS | Antinous Technology Company Limited | FUJITA, KATRINA R | 2672 | §102§103 | Non-Final OA | — | Pending | Nov 27, 2024 |
| 18958722 | COMPOSITE BUILDING MATERIALS AND METHODS OF MANUFACTURE | Rise Building Products LLC | CHOI, PETER Y | 1786 | §103 | Final Rejection | — | Pending | Nov 25, 2024 |
| 18953864 | CRYSTALLINE FORMS OF ALDH2 MODULATORS | Sophrosyne Pharmaceuticals Limited | BRAUN, MADELINE E | §101§112Other | Non-Final OA | — | Pending | Nov 20, 2024 | |
| 18945759 | SYSTEMS AND METHODS FOR PATIENT TARGETED THERAPY DEVELOPMENT | Flagship Pioneering Innovations Vi, LLC | PAULS, JOHN A | 3683 | §101§103DP | Final Rejection | 23d overdue | Pending | Nov 13, 2024 |
| 18941833 | COSMETIC COMPOSITIONS | Eleblend LLC | PHAN, DOAN THI-THUC | 1613 | §102§103§112 | Non-Final OA | — | Pending | Nov 08, 2024 |
| 18941986 | 3-(SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Deuterx, LLC | WARD, PAUL V | 1622 | DP | Non-Final OA | — | Pending | Nov 08, 2024 |
| 18938818 | COMPACT LIQUID CHROMATOGRAPHY SYSTEM PROVIDING THERMAL MANAGEMENT AND DETECTION | Waters Technologies Corporation | SINGER, DAVID L | 2855 | §103Other | Non-Final OA | — | Pending | Nov 06, 2024 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial74.5% of resolved applications prosecuted by Goodwin Procter LLP were allowed, across 12,363 applications in USPTO records.
3.52 office actions per allowed application on average.
395 pending office actions as of October 2026, for 190 clients, before 326 examiners in 129 art units.
